Oncogenic Ras triggers a permanent cell-cycle arrest known as oncogene-induced senescence (OIS) that constitutes a relevant tumor suppressor mechanism. Ris1 (Ras-induced senescence-1) is a novel gene that was identified in a screen as specifically upregulated during Ras-induced senescence, and that is located at a chromosomal region, 3p21.3, frequently lost in human cancer. Moreover, Ris1 is highly conserved in vertebrates, does not present paralogs, and its sequence does not reveal similarities with other proteins or domains. To analyse the physiological function of Ris1 and test its putative role as a tumor suppressor gene, we have generated mutant mice deficient for this gene. Ris1-null mice are viable, fertile, develop normally and do not display any obvious abnormalities. Of relevance, Ris1-deficient mice had a normal lifespan and did not exhibit predisposition to spontaneous tumors or to tumors induced by chemical carcinogens. Finally, Ris1-deficient embryonic fibroblasts were indistinguishable from wild-type cells regarding their proliferation properties, immortalization, senescence and oncogenic transformation. These findings do not support a role of Ris1 in tumor suppression or in OIS.
Introduction
The constitutive activation of a proto-oncogene in the context of a normal cell represents a major deregulation of cellular homeostasis. Normal cells respond to this loss of homeostasis by undergoing either apoptosis or cellcycle arrest, thus effectively preventing the expansion of cells carrying activated oncogenes (Weinberg, 1997; Bringold and Serrano, 2000; Lowe et al., 2004) . Notably, oncogenic Ras triggers an irreversible proliferative arrest that is reminiscent of replicative senescence (Serrano et al., 1997; Lin et al., 1998) . In order to safeguard against Ras-driven neoplastic transformation, cells activate the main tumor suppressor pathways ARF/p53 and INK4a/Rb, which together trigger cellular senescence; in contrast, those cells harboring mutations in these pathways bypass senescence and become neoplastically transformed (Bringold and Serrano, 2000; Lowe et al., 2004) . Recent evidence has demonstrated that oncogene-induced senescence (OIS) is a relevant in vivo response crucial for protection against cancer development (Braig et al., 2005; Chen et al., 2005; Collado et al., 2005; Michaloglou et al., 2005) .
As part of our studies on the identification of new specific markers and putative mediators for Ras-induced senescence, we identified a novel gene Ris1 (Ras-induced senescence-1), which is specifically activated during OIS (Barradas et al., 2002) . Ris1 is highly upregulated in Ras-senescent human fibroblasts, not being induced in the same conditions if senescence is bypassed (i.e., in the concomitant presence of E1a). Moreover, Ris1 was not induced by other forms of senescence, such as replicative senescence, or by other forms of cellular stress or organismal aging, suggesting a specific association with Ras-induced senescence (Barradas et al., 2002) . Importantly, the chromosomal location of Ris1 at 3p21.3 is highly provocative, because this region is frequently deleted in a variety of human solid cancers and, more specifically, Ris1 is contained in a short segment of 1.4 Mb mapped by other investigators for its tumor suppressive activity (Imreh et al., 2003; Petursdottir et al., 2004) . Indeed, high frequency of loss of heterozygosity has been demonstrated for Ris1 in breast carcinomas (Silva et al., 2006) . Therefore, based on its association to OIS and its chromosomal location, Ris1 could be a tumor suppressor gene.
Analysis of the amino-acid sequence of Ris1 indicates that this protein is highly conserved through vertebrate evolution, but is not present in the genomes of less complex model organisms, such as yeast, Caenorhabditis elegans or Drosophila melanogaster. In addition, Ris1 does not present paralogs in the genome and does not show sequence homology to any previously described protein domain that could allow functional predictions. Finally, other investigators independently identified Ris1 as a brain-specific membrane protein, which could play a role in a receptor complex that signals neuronal survival (Hama et al., 2001) . To uncover the physiological function of Ris1 and test its putative role as a tumor suppressor gene, we have generated mutant mice lacking Ris1.
Results

Expression of Ris1 in adults and during embryonic development
To study the biological function of Ris1, we began by analysing Ris1 expression in adult mice. As shown in Figure 1a , transcription derived from Ris1 was detected in most adult tissues, including the brain, lymph nodes, spleen, liver, kidney and the small and large intestines, and it was almost undetectable in thymus and testis. The major site of Ris1 expression was brain, supporting previous studies indicating a role for Ris1 in the nervous system (Hama et al., 2001) .
Differentiation often involves changes in proliferation rates or even induction of cell-cycle arrest. Therefore, it was of interest to study Ris1 expression during embryonic development. We determined the temporal expression pattern of mouse Ris1 at different embryonic stages using reverse transcription-polymerase chain reaction (RT-PCR). Interestingly, Ris1 mRNA levels were modulated during embryonic development; thus, Ris1 could be clearly detected at day E9.5, it was downregulated at day E10.5 and expressed again at day E11.5, its levels increasing steadily until day E14.5 ( Figure 1b) . To investigate the spatial expression of Ris1 during embryonic development, we performed wholemount in situ hybridizations at days E9.5, E10.5 and E11.5 of development. As shown in Figure 1c , Ris1 expression was indeed dynamically regulated at different stages of embryonic development. Specifically, Ris1 mRNA is ubiquitous at day E9.5, showing especially high levels in the endoderm and excluded only from the heart. At day E10.5, Ris1 expression is more restricted being particularly prominent in the neural tube and in the limb buds. Finally, at day E11.5, Ris1 levels are very high in the brain, neural tube and, again, at defined regions in the limb buds. Altogether, these observations implicate that Ris1 expression is actively regulated during development, particularly in the nervous system and in the developing limbs.
Generation of Ris1-null mice To examine the in vivo function of Ris1 and its putative role in tumorigenesis, we generated mice with a targeted deletion of the entire Ris1 gene. Ris1 is encoded by a single exon and we substituted the complete coding exon by a neo-selection cassette, therefore excluding the possibility of expression of truncated forms (Figure 2a) . Southern blot and PCR analyses confirmed the elimination of Ris1 (Figure 2b and c) . Moreover, RT-PCR analyses using total RNA prepared from the brain, spleen and kidney confirmed the complete elimination of Ris1 expression in Ris1 -/-mice ( Figure 2d ).
Lifespan and spontaneous cancer susceptibility of Ris1-null mice Ris1-null mice were born at the expected Mendelian ratio, were fertile, developed normally and displayed no overt phenotypes (data not shown). We examined the gross anatomy and histology of Ris1 À/À mice and found no differences with wild-type mice. As an example, Figure 3a shows histological preparations from the brain, spleen and kidney, which correspond to tissues Expression of Ris1 in total embryos at the indicated developmental stages. Amplification of actin was used as a control for RNA integrity. For both panels a and b, Ris1 transcript levels were determined by RT-PCR using total RNA extracts. (c) Whole-mount in situ hybridizations using an antisense probe against Ris1. Embryos at days E9.5, E10.5 and E11.5 are shown, as indicated. Control sense probes were used for all hybridizations and it is shown, as an example, for day E9.5 (embryo at the right side).
Phenotype of Ris1-null mice M Nieto et al with high levels of Ris1 expression (see above Figure 1a ). We have studied the long-term viability, aging and spontaneous tumorigenesis of Ris1-null mice. As can be seen in Figure 3b , mice lacking Ris1 have a lifespan that is indistinguishable from their wild-type littermates. Analysis of the causes of death did not reveal pathologies specifically associated to Ris1-null mice; of relevance, this includes a similar incidence of aging-associated malignant tumors (see Figure 3b , inset), which consist mostly in lymphomas, sarcomas and histiocytic tumors (data not shown). From these observations, we conclude that the absence of Ris1 is not essential for embryonic development or adult life, does not affect long-term viability under standard laboratory conditions and does not increase the incidence of aging-associated spontaneous malignant tumors.
Chemical carcinogenesis in Ris1-null mice To interrogate whether Ris1 deficiency affects cancer development, we evaluated the susceptibility of Ris1-null mice using two protocols of chemical carcinogenesis. First, we performed a classical two-stage skin carcinogenesis consisting of a single application of 7,12-dimethylbenz[a]anthracene (DMBA) followed by repeated applications of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) (Quintanilla et al., 1986) . As shown in Figure 4a , there were no significant differences in the number of papillomas per mouse or in their size, although it should be mentioned that the papillomas observed in Ris1-null mice were slightly bigger than those in wild-type mice (Figure 4a ). This modest difference in size did not reach statistical significance, but leaves open the possibility that the absence of Ris1 could favor tumor growth in this particular setting. We also evaluated a different model of tumor induction by subcutaneous (s.c.) injection of the chemical carcinogen 3-methyl-cholanthrene, which results in the generation of fibrosarcomas (Qin et al., 2002) . Tumors arose with the same latency and had the same incidence in both groups, regardless of the presence or absence of Ris1 (Figure 4b ). Taken together, these data strongly suggest that Ris1 plays a minor or insignificant role as a tumor suppressor for skin papillomas and fibrosarcomas.
Proliferation, immortalization and neoplastic transformation of Ris1 À/À MEFs To examine the possibility that Ris1 could play a role during the cell cycle, we measured several proliferative parameters in primary MEFs (mouse embryo fibroblasts) derived from Ris1 À/À E13.5 embryos. In the first place, we studied cell growth under standard serum conditions, that is, 10% serum, and we found no differences in cellular proliferation rates in Ris1 -/-MEFs compared to wild-type MEFs (Figure 5a , left panel). Moreover, Ris1 -/-MEFs as well as wild-type MEFs were not able to proliferate under more restrictive conditions, that is, 5% serum, whereas cells deficient in well-established tumor suppressor genes, such as INK4/ARF À/À MEFs, were able to overcome growth factor shortage ( Figure 5a , right panel). As an additional assay, we measured the re-entry into the S phase of quiescent cells stimulated with serum ( Figure 5b ). This experiment revealed that wild-type and Ris1
-/-MEFs displayed comparable cell-cycle reentry kinetics, providing further evidence that absence of Ris1 does not deregulate the cell cycle in a significant manner.
We studied the behavior of Ris1 -/-MEFs in the context of cellular senescence. It is known that several important tumor suppressor genes participate in the response to the chronic stress associated to standard in vitro culture conditions and the ensuing permanent proliferative arrest or senescence induced by culture stress. Serial passage of several independent primary Ris1 -/-MEFs showed entry into senescence in a manner similar to wild-type MEFs (Figure 5c ). This is in sharp contrast to MEFs lacking INK4/ARF À/À MEFs, which bypass culture stress-induced senescence (Serrano et al., 1996) . Phenotype of Ris1-null mice M Nieto et al upon introduction of oncogenic Ras (data not shown). Consistent with this, we evaluated the transformation properties of Ris1 À/À MEFs performing classical fociformation assays upon calcium transfection (see e.g., Pantoja and Serrano, 1999) . As reported previously (Serrano et al., 1996 (Serrano et al., , 1997 , primary INK4/ARF À/À MEFs were susceptible to neoplastic transformation by oncogenic Ras, whereas Ris1 À/À cells were refractory to transformation, thus behaving like wild-type MEFs (Figure 5e ). Together, these data indicate that Ris1 does not play an essential role in senescence, neither induced by culture stress nor by oncogenic stress.
Discussion
Ris1 was identified in a screen looking for candidates participating in the protective, senescence-like, response elicited by oncogenic Ras in primary human fibroblasts (Barradas et al., 2002) . To address the physiological function of Ris1, we first studied its expression pattern in mice. Ris1 was found ubiquitously expressed in adult mice, being brain the most prominent tissue, which is in support of the proposed role of Ris1 in neuronal survival (Hama et al., 2001) . Moreover, the analysis of Ris1 expression during embryonic development confirmed high levels of expression in the nervous system and also showed a dynamic regulation at different developmental stages, thus suggesting a role of Ris1 during development.
To evaluate the putative role of Ris1 as a tumor suppressor, we generated Ris1-null mice using a targeted deletion in murine embryonic stem (ES) cells. Ris1-null mice were viable, fertile and healthy and did not display any obvious phenotype. The fact that Ris1-null mice developed normally indicates that, despite its regulated expression during development, it is not essential for this process. The dispensability of Ris1 has enabled us to study the impact of Ris1 on lifespan and cancer susceptibility. Mice lacking Ris1 thrived to old age in a manner comparable to littermate controls and were not predisposed to spontaneous cancer. Moreover, Ris1-null mice showed no increased susceptibility to chemically induced epithelial or mesenchymal tumors, that is, skin papillomas and fibrosarcomas, respectively. These observations do not support a role of Ris1 in tumor suppression. In accordance with this conclusion, a recent analysis of Ris1 in primary human breast carcinomas did not show a statistically significant Phenotype of Ris1-null mice M Nieto et al correlation between decreased Ris1 expression and poor prognosis or other pathological parameters (Silva et al., 2006) . These results point to other candidate tumor suppressor genes at 3p21, different from Ris1, as the real targets of the deletions frequently found in human cancer, such as SEMA3F or RASSF1A (Xiang et al., 2002; van der Weyden et al., 2005) . Finally, we tested the impact of Ris1 deficiency in the context of Ras-induced senescence, scenario in which the gene was originally isolated. After an extensive study of Ris1 À/À -deficient MEFs including proliferation, S-phase entry, replicative senescence, immortalization, Ras-induced senescence and Ras-induced transformation, we could not observe any significant difference with wild-type MEFs. Therefore, we conclude that the absence of Ris1 does not result in the deregulation of cell proliferation, and does not affect senescence or neoplastic transformation in MEFs. Taken together, our results suggest that Ris1 is not involved in Ras-induced senescence and do not support a role of Ris1 in tumor suppression.
Materials and methods
Targeting vector
A genomic DNA clone was isolated by screening a bacterial artificial chromosome (BAC) library ('Down-to-the-well', Genome Systems, St Louis, MO, USA) derived from the 129Sv/J mouse strain. The genomic insert was analysed with restriction enzymes, Southern blotting, subcloning and sequencing. Plasmid pPNT, containing the pgk-neo and pgk-tk (thymidine kinase) selection markers, was used to generate the Ris1 targeting vector. The targeting vector was formed by a 1.5 Kb fragment 'upstream' of Ris1 obtained with EcoRI and ApaI from the genomic BAC and subcloned into pPNT as an EcoRI-KpnI fragment (the KpnI site was introduced in the subcloning), and by a 6.6 kb fragment 'downstream' of Ris1 obtained with PstI from the genomic BAC and subcloned into pPNT as a XhoI-NotI (these restriction sites were introduced in the subcloning) (Figure 2a) . The 2.4 kb neo-cassette was used as a positive marker and replaces a 4 kb genomic fragment containing Ris1 (Figure 2a) .
Generation of Ris1-null mice
The targeting vector was linearized by digestion with NotI, electroporated into R1 ES cells, and selected for homologous recombination with G418 and ganciclovir. Positive clones were screened by Southern blot following XbaI digestion of genomic DNA and probed with a radiolabeled probe not contained in the targeting construct (Figure 2a) . A 4.9 kb fragment was detected from the wild-type allele and a 2.3 kb fragment from the mutant allele (Figure 2b) . The targeted ES cell clones were expanded and subsequently aggregated with CD1 morulae to generate chimeras. All the assays shown in this work were performed with mice or embryos in a mixed genetic background C57BL6;129Sv (50:50).
PCR genotyping of Ris1-deficient mice After initial verification of genotypes by Southern blotting, the mice were genotyped by PCR (Figure 2c ). The following primer sequences were employed: for the wild-type allele, primers wt-2F (5 0 -GCGGAGCCGAGCAGGGGAATC-3 0 ) and wt-1R (5 0 -CAGCAGACGCGGGGTGGAGTGTT-3 0 ), which amplify a 418 bp fragment, and for the mutant allele, primers neo-1 (5 0 -CCTTCTATCGCCTTCTTGAC-3 0 ) and ko-2F (5 0 -AACTGACACATTTGGAAACC-3 0 ), which amplify a 423 bp fragment. Reactions were carried out separately under standard conditions and using an annealing temperature of 571C and 10% dimethyl sulfoxide for the null allele reaction.
RT-PCR analysis Total RNA was extracted from different developmental stages or from adult tissues, and 1 mg was used to perform the RT. The PCR reaction was carried out for 35 cycles of denaturation (941C for 30 s), annealing (601C for 30 s) and extension (721C for 25 s) using two specific oligonucleotides 5 0 -CGAC GAGCGGAGTCTGAAGAGG-3 0 (Ris1-sense), and 5 0 -GG GGTGGAGTGTTCGTTGGTGA-3 0 (Ris1-antisense). The integrity of RNA was verified by similar RT-PCR experiments using specific primers for actin.
Whole-mount in situ hybridization Embryos were collected at days E9.5, E10.5 and E11.5 and fixed in 4% paraformaldehyde in phosphate-buffered saline (O/N, 41C). Before hybridization, embryos were treated with proteinase K 10 mg/ml (Sigma, Cambridge, UK), for 15 min (E9.5), 20 min (E10.5) or 25 min (E11.5), and fixed again in a mixture containing 4% paraformaldehyde and 0.2% glutaraldehyde, for 20 min at RT. Pre-hybridization was carried out for 1 h at 651C in hybridization solution (50% formamide, standard sodium citrate 1.3 Â , 5 mM ethylenediaminetetraacetic acid (pH 8), heparin 100 mg/ml, 0.2% Tween-20, 0.5% 3-[(3-cholamido propyl)-dimethylammonio]-2-hydroxy-1-propanesulfonic acid and 50 mg/ml yeast DNA). Specific digoxigenin (DIG)-antisense RNA probes against Ris1 were synthesized using a DIG Labeling Kit (Roche Molecular Biochemicals, Basel, Switzerland) and hybridized in the same solution and temperature O/N. A control DIG-sense RNA probe was carried out in parallel for every hybridization. The final detection of DIG probes was carried out using anti-DIG antibodies coupled to alkaline phosphatase (DIG Detection Kit, final dilution 1/2000, Roche Molecular Biochemicals).
Histological analysis
Tissues were fixed in 10% neutral-buffered formalin. Fixed tissues were embedded in paraffin by standard procedures. Blocks were sectioned (5 mm) and stained with hematoxylin and eosin.
Chemical carcinogenesis
Mouse experimentation was carried out in accordance with the guidelines of the CNIO regarding the care and use of laboratory animals. For DMBA-TPA-induced carcinogenesis, Ris1 À/À and wild-type mice were shaved and treated with DMBA (20 mg in 200 ml of acetone; Sigma, Cambridge, UK) 48 h after shaving. Mice were subsequently treated twice weekly with TPA (10 À4 M in acetone; 200 ml; Sigma) for 15 weeks. Two control mice of each genotype were treated with acetone only.
For 3-methylcholanthrene (3-MC) chemical carcinogenesis, groups of Ris1 À/À (n ¼ 13) and wild-type (n ¼ 13) male mice were injected s.c. with a freshly prepared solution of 3-MC in olive oil (100 mg in 100 ml per mouse) in each flank. Mice were observed weekly for tumor development over the course of 22-30 weeks. Tumors larger than 5 mm and showing progressive growth were counted as positive. Mice were killed when they had an overt tumor mass or if moribund.
Phenotype of Ris1-null mice M Nieto et al
